Compare Citius Pharmaceuticals Inc (CTXR) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vital Farms Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Vital Farms Inc trades at $9.49 (market cap $405.27M). The key difference: Vital Farms Inc is far larger — about 29.8× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 1,810,837). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Vital Farms Inc for 14 Days on average.
| CTXR | VITL | |
|---|---|---|
Market Cap | $13.62M | $405.27M |
Volume | 132,438 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $43.68 |
52-Week Low | $0.48 | $8.28 |
Typical Hold Time | 16 Days | 14 Days |
Enterprise Value | $3.79M | $492.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Vital Farms (VITL) trades at $9.45, up 2.27% today, amid a challenging fundamental backdrop. The stock exhibits a bearish technical trend, with recent earnings showing significant pressure on profitability. Revenue for 2025 was $759.44M with a net income of $66.28M, but 2026 projections indicate a sharp decline in net income to near breakeven. Recent news highlights strategic review discussions and institutional investment activity, contributing to volatile price action.
The outlook is mixed; analyst consensus is bullish with a $13.11 price target, but near-term risks from egg pricing pressure and weak profitability metrics pose challenges. Investment opportunity hinges on successful execution of strategic options and margin recovery, while downside risks include sustained industry oversupply and cash flow constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
